Abbott Biaxin XL
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Company's macrolide antibiotic clarithromycin gains approval Aug. 6 for new indication to treat mild to moderate community-acquired pneumonia caused by H. influenzae, H. parainfluenzae, M. catarrhalis, S. pneumoniae, C. pneumoniae and M. pneumoniae, in a seven-day treatment regimen